Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Renin–angiotensin system inhibitor (RASi), sodium–glucose cotransporter 2 inhibitors (SGLT2i), and finerenone have shown benefits in diabetic kidney disease (DKD), but real-world evidence for their combined use remains limited. This study assessed triple therapy on renal outcomes and safety in Chinese patients.
We prospectively enrolled patients with DKD receiving angiotensin II receptor blockers (ARB) and SGLT2i therapy and stratified them into mineralocorticoid receptor antagonist therapy (MRA) and non-MRA groups based on finerenone. Propensity score matching (PSM) balanced baseline characteristics. Changes in 24-hour urine protein, estimated glomerular filtration rate (eGFR) and safety were evaluated, with subgroup analyses in patients with high urine albumin-to-creatinine ratio (UACR ≥ 5000 mg/g) or low eGFR (< 25 ml/min/1.73㎡).
99 subjects were enrolled, with 39 per group after PSM. Compared with the non-MRA group, the MRA group significantly reduced 24-hour urine protein at 1 month (mean [95% CI]: 3.36 [2.45, 4.60] vs. 6.21 [4.53, 8.50]; P = 0.007), with similar trends at 3 and 6 months, and eGFR remained stable. Among subjects with UACR ≥ 5000 mg/g, 24-hour urine protein decreased at 6 months (mean [95% CI]: 3.74 [2.33, 5.99] vs. 7.66 [4.78, 12.28]; P = 0.04). In patients with baseline eGFR < 25 ml/min/1.73㎡, 3 of 5 showed reductions in 24-hour urine protein and improvements in eGFR. No patients developed hyperkalemia requiring intervention.
The triple therapy of ARB, SGLT2i, and finerenone further reduced proteinuria, maintained stable eGFR but was well tolerated, potentially benefiting DKD patients at different disease stages.
